Florence Brunet-Possenti
Florence Brunet-Possenti is an expert in Dermatology at Hôpital Bichat-Claude-Bernard (France). Florence Brunet-Possenti has authored 233 publications, the most recent in 2026, and is an investigator in 9 clinical trials, 4 of them ongoing. SLR score: 743 (community average: 125). How the SLR is computed.
LeadR Profile
Dermatology
Subspecialties: Oncology - Public Health - Immunology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1988 - 2025
Number : 233
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Prevalence and risk factors for high-risk human papillomavirus infection in patients with immune-mediated inflammatory diseases: a prospective study. PMID 42457210 — uterine cervical neoplasms, neoplasms, rheumatic diseases, prevalence, risk factors, therapeutics, alphapapillomavirus, papillomavirus infections, infections, prospective studies, human papillomavirus viruses | RMD Open | 2026 | 0 |
| Real-world outcomes of immune checkpoint inhibitors in people with HIV and skin cancer: a multicentre study. PMID 41396687 — skin, cells, safety, melanoma, neoplasms, sarcoma, immune checkpoint inhibitors, hiv, therapeutics, skin neoplasms | Oncologist | 2025 | 0 |
| Neoadjuvant ipilimumab and nivolumab for resectable stage II mucosal melanoma. PMID 41297185 — sexually transmitted diseases, melanoma, nivolumab, ipilimumab, dermatology | Ann Dermatol Venereol | 2025 | 0 |
| Benefit of immune checkpoint inhibitors as adjuvant treatment for acral melanomas. PMID 41277783 — sexually transmitted diseases, melanoma, foot, skin diseases, immunotherapy, drug-related side effects and adverse reactions, immune checkpoint inhibitors, neoplasm metastasis, chemotherapy, adjuvant, nivolumab, therapeutics | J Eur Acad Dermatol Venereol | 2025 | 0 |
| Impact of the COVID-19 pandemic on melanoma: A retrospective study from the French clinical database of melanoma patients (RIC-Mel). PMID 40912206 — sexually transmitted diseases, lymph nodes, melanoma, retrospective studies, covid-19, lymph, diagnosis, pandemics, therapeutics, dermatology | Ann Dermatol Venereol | 2025 | 0 |
Clinical Studies 9
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 1
Ongoing Clinical Trials
4 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Follow up of a French National Cohort of Patients With Cutaneous Squamous Cell Carcinoma Requiring Systemic Treatment NCT07606508 — skin, cells, carcinoma, squamous cell, neoadjuvant therapy, therapeutics, carcinoma, cutaneous squamous cell carcinoma | N/A | Recruiting | 2021 |
| Host Genome Methylation a Screening Tool in Anal Cancer Detection NCT06792604 — vulvar neoplasms, anus neoplasms, neoplasms, genome, cell biology, hiv, transplants, wounds and injuries, cytology, men, women | N/A | Recruiting | 2024 |
| Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First Line Therapy in Patients With Advanced Melanoma NCT06697301 — toll-like receptors, safety, melanoma, neoplasms, neoplasm metastasis, therapeutics, toll-like receptor 7 | Phase 2/Phase 3 | Recruiting | 2025 |
| Study of a Strategy Integrating Adjuvant Radiation Therapy Versus Strategy Based on Monitoring in the Treatment of Carcinomas Spinocellular With High Risk of Recurrence NCT06692556 — radiotherapy, skin, cells, carcinoma, squamous cell, brachytherapy, neoplasms, radiotherapy, adjuvant, beds, therapeutics, nervous system, carcinoma, cutaneous squamous cell carcinoma | Phase 3 | Recruiting | 2025 |
LeadR Networks
Main global connection map